U.S. MINIMALLY INVASIVE BENIGN PROSTATIC HYPERPLASIA (BPH) THERAPY SYSTEMS MARKET

118 Pages | 31 Exhibits | 2011 Analysis | Forecasts Through 2015

OVERVIEW:
Benign prostatic hyperplasia (BPH), or the noncancerous enlargement of the prostate gland, is a common condition associated with aging. While the prostate grows throughout a man's lifetime, bothersome growth typically begins at age 40, and by approximately age 60 more than half of men will have experienced at least some symptoms of BPH; by age 80, up to 80% to 90% of men become symptomatic. It is estimated that nearly 15 million men in the United States and 30 million men worldwide experience symptoms of BPH; of this number, an estimated 25% require pharmaceutical or surgical treatment. Due to the aging of the population, the number of men with the condition is expected to follow an upward trend. This presents a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe and effective alternative to drugs and invasive surgery, which carry greater risk of undesirable or significant side effects and complications.

While current economic conditions continue to restrain market growth, the U.S. market for minimally invasive bariatric surgical devices is expected to exhibit relatively good growth over the next 5 years. Valued at an estimated $147.5 million in 2010, the U.S. minimally invasive benign prostatic hyperplasia therapy systems market is expected to increase at a compound annual rate of 2.4%, with sales reaching more than $166 million in 2015. The largest segment, laser BPH therapy, is expected to drive market growth over the forecast period-expanding at a comparatively higher rate of 4.6%-at the expense of minimally invasive office-based therapies.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include transurethral microwave thermotherapy (TUMT); transurethral needle ablation (TUNA); holmium laser ablation of the prostate (HoLAP); photoselective vaporization of the prostate (PVP), or Greenlight Laser Therapy; transurethral resection of the prostate (TURP); and other energy-based technologies.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY 

i. Causes 
ii. Symptoms 
iii. Diagnosis 
iv. Treatment 
	a. Prescription Drugs 
	b. Minimally Invasive Therapy 
	c. Surgery 
	d. Stents 
v. Minimally Invasive Benign Prostatic Therapy Systems Market 
	a. Procedure Volumes Forecast 
	b. Market Forecast 
vi. Methodology 

Exhibit ES-1: The Prostate and Urine Flow 
Exhibit ES-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia 
Exhibit ES-3: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2010-2015 
Exhibit ES-4: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015 

1. CLINICAL OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA

1.1 Causes 
1.2 Symptoms 
1.3 Diagnosis 
1.4 Treatment 
	1.4.1 Prescription Drugs 
	1.4.2 Minimally Invasive Therapy 
	1.4.3 Surgery 
	1.4.4 Stents 

Exhibit 1-1: The Prostate and Urine Flow 
Exhibit 1-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia 
 
2. MINIMALLY INVASIVE BENIGN PROSTATIC HYPERPLASIA THERAPY SYSTEMS

2.1 Transurethral Microwave Thermotherapy 
	2.1.1 CoreTherm:  ProstaLund Operations 
	2.1.2 Prolieve System:  Boston Scientific 
	2.1.3 Cooled ThermoTherapy:  Urologix 
	2.1.4 TherMatrx Office Thermo Therapy: American Medical Systems 
2.2 Transurethral Needle Ablation:  Medtronic 
2.3 Laser- and Other Energy-Based Therapies 
	2.3.1 Holmium Laser Ablation/Enucleation of the Prostate 
		2.3.1.1 VersaPulse PowerSuite:  Lumenis 
	2.3.2 Photoselective Vaporization of the Prostate 
		2.3.2.1 GreenLight Laser Therapy: American Medical Systems 
	2.3.3 Other Laser-Based Technologies 
		2.3.3.1 EVOLVE Laser System:  Biolitec 
		2.3.3.2 Odyssey Holmium Laser: Convergent Laser Technologies 
		2.3.3.3 PlasmaButton Vaporization Therapy: Gyrus ACMI/ Olympus America/Olympus 
		2.3.3.4 Thulium Lasers:  HealthTronics/Endo Pharmaceuticals 
	2.3.4 Other Energy-Based Technologies 
		2.3.4.1 Aptocine:  Light Sciences Oncology 
2.4 Prostatic Stents 
	2.4.1 The Spanner Prostatic Stent:  AbbeyMoor Medical 
	2.4.2 CoreFlow Soft Stent:  ProstaLund Operations 
	2.4.3 UroLume Urethral Stent: American Medical Systems 
2.5 Market Analysis 
	2.5.1 Procedure Volumes Forecast 
	2.5.2 Market Forecast 
		2.5.2.1 Market Drivers 
		2.5.2.2 Market Limiters 
2.6 Competitive Analysis 

Exhibit 2-1: Advantages and Disadvantages of Minimally Invasive Therapy for Benign Prostatic Hyperplasia 
Exhibit 2-2: 2011, Selected Microwave- and Radiofrequency-Based  Benign Prostatic Hyperplasia Therapy Systems 
Exhibit 2-3: The CoreTherm System 
Exhibit 2-4: Five-Year Clinical Comparison of Symptomatic Reduction in Benign Prostatic Hyperplasia Using the CoreTherm System and Competitive Treatments 
Exhibit 2-5: The Schelin Catheter 
Exhibit 2-6: The CoolWave and Targis Systems 
Exhibit 2-7: The Cooled ThermCath Advance Catheter 
Exhibit 2-8: Cooled ThermoTherapy, Selected Five-Year Clinical Trial Results 
Exhibit 2-9: Comparison of Cooled ThermoTherapy with Drug Therapy, Selected Clinical Results 
Exhibit 2-10: The Prostiva Radiofrequency Therapy System 
Exhibit 2-11: Holmium Laser Ablation of the Prostate Using the VersaPulse PowerSuite Laser System 
Exhibit 2-12: Selected Advantages of Holmium Laser Ablation Using the VersaPulse PowerSuite Compared with Photoselective Vaporization Using the GreenLight PV 
Exhibit 2-13: The GreenLight High Performance System 
Exhibit 2-14: The GreenLight Xcelerated Performance System 
Exhibit 2-15: The MoXy Liquid Cooled Fiber 
Exhibit 2-16: The EVOLVE Laser System 
Exhibit 2-17: PlasmaButton Vaporization Therapy 
Exhibit 2-18: Aptocine's Effects on Tumor Cells, and Selected Benefits of Aptocine Treatment 
Exhibit 2-19: The Spanner Prostatic Stent 
Exhibit 2-20: The CoreFlow Soft Stent 
Exhibit 2-21: Benefits of the UroLume Urethral Stent 
Exhibit 2-22: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy,Procedure Volumes Forecast, 2010-2015 
Exhibit 2-23: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015 
Exhibit 2-24: 2010, Benign Prostatic Hyperplasia Laser Therapy Systems Market, Share by Supplier 
Exhibit 2-25: 2010, Transurethral Microwave Thermotherapy and Transurethral Needle Ablation Systems Market, Share by Supplier 

3. COMPANY PROFILES

3.1 American Medical Systems, Inc. 
3.2 Boston Scientific Corporation 
3.3 Lumenis LTD 
3.4 Medtronic, Inc. 
3.5 Olympus America/Olympus Corporation 
3.6 ProstaLund Operations AB 
3.7 Urologix, Inc. 


APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. American Medical Systems, Inc.
  2. Boston Scientific Corporation
  3. Lumenis LTD
  4. Medtronic, Inc.
  5. Olympus America/Olympus Corporation
  6. ProstaLund Operations AB
  7. Urologix, Inc.
Contact Us

Need help finding medtech research? Let us help you!